- Home
- ASRT vs ACET Comparison
ASRT vs ACET Comparison
Compare ASRT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- ACET
- Stock Information
- Founded
- ASRT 1995
- ACET 1947
- Country
- ASRT United States
- ACET United States
- Employees
- ASRT N/A
- ACET N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- ACET Health Care
- Exchange
- ASRT Nasdaq
- ACET Nasdaq
- Market Cap
- ASRT 84.6M
- ACET 93.1M
- IPO Year
- ASRT 1997
- ACET N/A
- Fundamental
- Price
- ASRT $0.89
- ACET $0.91
- Analyst Decision
- ASRT Strong Buy
- ACET Strong Buy
- Analyst Count
- ASRT 4
- ACET 4
- Target Price
- ASRT $3.19
- ACET $5.67
- AVG Volume (30 Days)
- ASRT 933.9K
- ACET 776.5K
- Earning Date
- ASRT 11-11-2024
- ACET 11-06-2024
- Dividend Yield
- ASRT N/A
- ACET N/A
- EPS Growth
- ASRT N/A
- ACET N/A
- EPS
- ASRT N/A
- ACET N/A
- Revenue
- ASRT $125,763,000.00
- ACET N/A
- Revenue This Year
- ASRT N/A
- ACET N/A
- Revenue Next Year
- ASRT $1.84
- ACET N/A
- P/E Ratio
- ASRT N/A
- ACET N/A
- Revenue Growth
- ASRT N/A
- ACET N/A
- 52 Week Low
- ASRT $0.73
- ACET $0.81
- 52 Week High
- ASRT $1.80
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- ASRT 42.24
- ACET 37.30
- Support Level
- ASRT $0.90
- ACET $0.81
- Resistance Level
- ASRT $1.04
- ACET $0.98
- Average True Range (ATR)
- ASRT 0.07
- ACET 0.08
- MACD
- ASRT -0.01
- ACET -0.00
- Stochastic Oscillator
- ASRT 28.11
- ACET 31.25
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.